Pacira BioSciences (PCRX) stock is drawing fresh attention after the company reported that UnitedHealthcare will provide separate reimbursement for its non opioid pain drug EXPAREL in outpatient surgical settings nationwide.

The UnitedHealthcare reimbursement decision and Pacira BioSciences’ recent additions to several Russell 2000 indices come as the stock trades at US$25.82, with a 30 day share price return of 13.49% and a 1 year total shareholder return of 11.39%. In contrast, the 3 year and 5 year total shareholder returns have declined 31.29% and 53.55% respectively, suggesting improving short term momentum against a weaker long term record.

If this kind of reimbursement driven story has your attention, it can be worth looking at other healthcare companies using AI in similar ways by checking the 40 healthcare AI stocks

For Pacira BioSciences, the recent rebound comes just as reimbursement access for EXPAREL has shifted meaningfully. This raises a key issue for investors: is this move mainly about better business fundamentals, or a swing in sentiment that valuation now needs to test?

Most Popular Narrative: 32.1% Undervalued

Pacira BioSciences is trading at $25.82 against a widely followed fair value narrative of $38, putting the focus squarely on how that gap is being justified.

The J&J MedTech partnership for ZILRETTA effectively doubles sales coverage and unlocks access to broad, untapped physician networks in rheumatology, sports medicine, and pain management, potentially leading to a dramatic acceleration in ZILRETTA revenues and significant EPS accretion earlier than expected.

Read the complete narrative. Read the complete narrative.

Want to understand why this Pacira BioSciences fair value sits well above today’s price? The narrative leans on faster revenue build, higher margins, and a future earnings multiple that assumes the current product set delivers much more than the recent track record suggests.

Result: Fair Value of $38 (UNDERVALUED)

However, investors also need to weigh risks, including potential pressure on Pacira BioSciences’ pricing from payers and its dependence on a relatively concentrated product portfolio.

Next Steps

Mixed messages on Pacira BioSciences so far? Take a closer look at the full picture now and weigh the 4 key rewards and 1 important warning sign.

Looking for more Pacira BioSciences style investment ideas?

If Pacira BioSciences has sharpened your focus, do not stop here. Use the screener to spot other stocks that align with your goals before the next move.

• Target potential mispricings by scanning companies that appear overlooked on quality and value using the screener containing 18 high quality undiscovered gems.
• Strengthen your portfolio’s foundation by filtering for companies that show robust finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Dial back portfolio stress by focusing on companies with steadier profiles using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.